Testing Part B Payment Cuts: Sequester Means Providers Get ASP+4%
This article was originally published in RPM Report
Executive Summary
Cutting the payment level for Medicare Part B drugs is a perennial budget proposal, but never gets very far in Congress. Now, thanks to the sequester, Part B payments have been cut from ASP+6% to ASP+4.3%. Will it stick?
You may also be interested in...
Oncologists Move Against Medicare Part B Drug Payment, Pricing ‘Attacks’
Remember what happened the last time physician groups opposed federal efforts to curtail Medicare spending on Part B drugs?
Cancer Drug Access Unaffected By Medicare Sequester, CMS’ Blum Says
Fears that sequestration cuts to Medicare Part B drug payments would lead to drug access issues have failed to materialize, CMS’ Jonathan Blum tells the FDA/CMS Summit.
Medicare Rx and the Sequester Impact: Making Headlines, But is There a Commercial Impact?
Two large pharmaceutical manufacturers weigh in on whether the sequester is impacting their injectables business. The answer so far: not really. The same story goes for the sequester and Part D, though Lilly is seeing higher than expected Part D discounts in 2013.